Tafinlar Plus Mekinist Combo Approved as Adjuvant Rx for BRAF V600-Mutant Melanoma

The FDA has approved the combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) for adjuvant treatment of patients who have BRAF V600-mutated melanoma  with lymph node involvement after complete resection.